NeoMatrix Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 5% Total Body Surface Area Burns
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Neomatrix Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06814717
- Locations
- 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
Phase 1 Healthy Volunteer Burn Therapy Study
Phase 1
Completed
- Conditions
- Burns
- Interventions
- Drug: cNP8Other: Placebo
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Neomatrix Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06223009
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
News
No news found